More than 13 different cancers are associated with obesity, although the precise mechanisms underpinning the obesity and cancer link are unclear. In July 2021, NCI published two funding opportunity announcements, RFA-CA-21-021 and RFA-CA-21-022, inviting applications for research projects and a coordinating center for the Metabolic Dysregulation and Cancer Risk Program. The Program, with participation from the Division of Cancer Control and Population Sciences, Division of Cancer Biology, Division of Cancer Prevention, and the Center to Reduce Cancer Health Disparities, reflects the cross-cutting interests in obesity and cancer research within NCI and the activities of the Trans-NCI Obesity and Cancer Work Group.
The overall purpose of the trans-NCI Metabolic Dysregulation and Cancer Risk Program is to enhance knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk in individuals and identify mechanisms that will enhance cancer risk prediction, screening for high-risk individuals in clinical settings, and potential targets for preventive and therapeutic interventions.
The Metabolic Dysregulation and Cancer Risk Program consists of one coordinating center and multiple research project grants. The project titles below link to additional information in NIH RePORTER.
- Ceramides as Novel Drivers of Metabolic Dysfunction and Colorectal Cancer
- Decoding Mechanisms Underlying Metabolic Dysregulation in Obesity and Digestive Cancer Risk
- Determine the Molecular and Metabolic Mechanisms by which A-FABP Links Dysregulated Lipid Metabolism-Induced Obesity/Breast Cancer Risk
- Determining the Contribution of Microbial-Derived Metabolites to Protective Immunity in Obesity-Driven Cancer Risk
- A Transdisciplinary Approach to Investigate Metabolic Dysregulation in Obese Parent and Child Dyads and Risk of Colorectal Cancer
- Metabolic Dysregulation and Cancer Risk Program Coordinating Center